Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
| Status: | Completed |
|---|---|
| Conditions: | Brain Cancer, Brain Cancer, Brain Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | January 1997 |
| End Date: | January 2001 |
Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors
RATIONALE: Determination of genetic markers for leukemia or non-Hodgkin's lymphoma that is
secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify
patients who are at risk for these cancers.
PURPOSE: Clinical trial to determine the presence of certain genes in patients who are
receiving treatment for Hodgkin's disease or childhood brain tumors.
secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify
patients who are at risk for these cancers.
PURPOSE: Clinical trial to determine the presence of certain genes in patients who are
receiving treatment for Hodgkin's disease or childhood brain tumors.
OBJECTIVES: I. Determine the frequency of chromosome 3, 11, and 21 aberrations in peripheral
blood lymphocytes (PBL) specifically associated with acute myelogenous leukemia in patients
with adult or pediatric Hodgkin's disease treated with radiotherapy and/or chemotherapy. II.
Determine the frequency of these aberrations in patients with pediatric central nervous
system tumors treated with radiotherapy and/or chemotherapy. III. Determine the
glutathione-S-transferase allotype, associated with human toxicological response to
carcinogen exposure, for these patients. IV. Determine the frequency of t(14;18) gene
rearrangement, associated with deregulation of the bcl-2 proto-oncogene in non-Hodgkin's
lymphoma, in PBL of these patients.
OUTLINE: An extra tube of blood is collected before, every 4 weeks during, and every 3
months after radiotherapy and/or chemotherapy. DNA is isolated from the blood sample and the
GSTM1, GSTT1, and various cytochrome P (CYP) 450 genotypes are determined by polymerase
chain reaction (PCR). Mononuclear leukocytes are analyzed for chromosome aberrations on
chromosome numbers 3, 11, and 21. Pretreatment karyotype and frequency of translocations are
determined for each patient. Peripheral blood lymphocyte DNA is also examined for t(14;18)
gene rearrangements.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 2 years.
blood lymphocytes (PBL) specifically associated with acute myelogenous leukemia in patients
with adult or pediatric Hodgkin's disease treated with radiotherapy and/or chemotherapy. II.
Determine the frequency of these aberrations in patients with pediatric central nervous
system tumors treated with radiotherapy and/or chemotherapy. III. Determine the
glutathione-S-transferase allotype, associated with human toxicological response to
carcinogen exposure, for these patients. IV. Determine the frequency of t(14;18) gene
rearrangement, associated with deregulation of the bcl-2 proto-oncogene in non-Hodgkin's
lymphoma, in PBL of these patients.
OUTLINE: An extra tube of blood is collected before, every 4 weeks during, and every 3
months after radiotherapy and/or chemotherapy. DNA is isolated from the blood sample and the
GSTM1, GSTT1, and various cytochrome P (CYP) 450 genotypes are determined by polymerase
chain reaction (PCR). Mononuclear leukocytes are analyzed for chromosome aberrations on
chromosome numbers 3, 11, and 21. Pretreatment karyotype and frequency of translocations are
determined for each patient. Peripheral blood lymphocyte DNA is also examined for t(14;18)
gene rearrangements.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 2 years.
DISEASE CHARACTERISTICS: Diagnosis of Hodgkin's disease Adult or child OR Diagnosis of
primary central nervous system (CNS) malignancy 16 and under Medulloblastoma Ependymoma
Brain stem glioma Astrocytoma Primitive neuroectodermal tumor (PNET) Proposed therapy must
include external beam radiotherapy and/or chemotherapy
PATIENT CHARACTERISTICS: Age: See Disease Characteristics Any age Performance status: Not
specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not
specified Renal: Not specified
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics
Surgery: Not specified
We found this trial at
1
site
Duke Comprehensive Cancer Center Leading-edge cancer care and research have been a hallmark of Duke...
Click here to add this to my saved trials
